4-[(5Z)-5-Benzylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]benzoic acid

BML-260 is a potent inhibitor of dual-specific phosphatases JSP-1 and DUSP22. BML-260 can activate UCP1 and thermogenesis in adipocytes in a JSP-1-independent manner. The effect of BML-260 on adipocytes is partially achieved through the activation of CREB, STAT3, and PPAR signaling pathways. BML-260 can be used in the research of inflammatory and proliferative disorders associated with JNK signaling dysfunction as well as obesity[1][2].

[1] Williams D R, et al. Targeting phosphatase DUSP22 ameliorates skeletal muscle wasting via Akt independent JNK-FOXO3a repression[J]. bioRxiv, 2024: 2024.04. 08.588643.
[2] Feng Z, et al. Identification of a rhodanine derivative BML-260 as a potent stimulator of UCP1 expression[J]. Theranostics, 2019, 9(12): 3501. DOI:10.7150/thno.31951
[3] ESRA ALBAYRAK. BML-260 promotes the growth of cord blood and mobilized peripheral blood hematopoietic stem and progenitor cells with improved reconstitution ability[J]. Journal of cellular biochemistry, 2022, 123 12: 2009-2029. DOI: 10.1002/jcb.30324